Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells
- 1 February 1989
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 38 (4) , 641-648
- https://doi.org/10.1016/0006-2952(89)90210-4
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Antitumor properties of vindesine-monoclonal antibody conjugatesCancer Immunology, Immunotherapy, 1985
- Immunohistochemical Reaction of Three Monoclonal Antibodies to Human Milk Fat Globule Membrane with Human Normal and Tumoral TissuesPublished by Elsevier ,1985
- Binding, Uptake and Subcellular Distribution of Two Monoclonal Antibodies to Human Milk Fat Globule Membrane Studied on Human Mcf 7 Breast Carcinoma CellsPublished by Elsevier ,1985
- Preparation of four daunomycin‐monoclonal antibody 79IT/36 conjugates with anti‐tumour activityInternational Journal of Cancer, 1984
- A CONJUGATE OF ADRIAMYCIN AND MONOCLONAL ANTIBODIES TO THY‐1 ANTIGEN INHIBITS HUMAN NEUROBLASTOMA CELLS IN VITROaAnnals of the New York Academy of Sciences, 1983
- Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugateBritish Journal of Cancer, 1983
- A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitroBritish Journal of Cancer, 1981
- Increased selectivity of drugs by linking to carriersPublished by Elsevier ,1978
- Lysosomotropic agentsBiochemical Pharmacology, 1974
- Chemotherapy through Lysosomes with a DNA-Daunorubicin ComplexNature New Biology, 1972